This document describes the analysis method for the pharmaceutical compound clozapine, used for the treatment of severely ill schizophrenic clients. The use of Zorbax SPE C18 EC cartridge significantly reduces levels of interfering substances in the bloodstream, allowing for accurate quantification of clozapine or clozapine-like compounds.
This document details a method for analyzing clozapine, a pharmaceutical compound used to treat schizophrenia, using the Zorbax SPE C18 EC cartridge. The procedure demonstrates how the cartridge significantly reduces interfering substances in blood samples, allowing for accurate quantitation via reversed-phase HPLC with high recovery rates for clozapine and norclozapine.
| Cartridge Capacity | 100 mg |
|---|---|
| Column Dimensions | 3.2mm x 100mm, 5um |
| Mobile Phase Composition | 28% Acetonitrile in 25mM Potassium Phosphate |
| Detection Wavelength | 245 nm |
| Flow Rate | 0.5 mL/min |
| Column Temperature | 40°C |
| Injection Volume | 20 uL |
| Clozapine Recovery | 103% |
| Norclozapine Recovery | 111% |
It is used to significantly reduce levels of interfering substances in blood samples, allowing for accurate quantitation of clozapine.
The recovery rate for clozapine is 103%.
Flurazepam is used as the internal standard, prepared at 1800 ng/ml in Deionized Water.